Cipher Pharmaceuticals Wins Arbitration Against Sun Pharmaceuticals

Cipher Pharmaceuticals ( (TSE:CPH) ) has provided an update.

Cipher Pharmaceuticals has received a favorable arbitration award in a contractual dispute with Sun Pharmaceuticals over the launch of Absorica LD® in Canada and ownership of clinical data. The arbitrator ruled in Cipher’s favor, granting them CAD $4.24 million in damages, future royalties on sales, and reimbursement of legal fees. Sun is contesting the decision in court, but Cipher plans to defend the award and pursue further claims against Sun for using its clinical data in other regions.

The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$15.50 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.

Spark’s Take on TSE:CPH Stock

According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.

Cipher Pharmaceuticals’ overall stock score is driven by strong financial performance and positive earnings call highlights, particularly the record-breaking revenue and strategic growth initiatives. However, technical indicators suggest bearish momentum, and valuation metrics indicate moderate attractiveness. The absence of a dividend yield and challenges in the U.S. licensing segment also weigh on the score.

To see Spark’s full report on TSE:CPH stock, click here.

More about Cipher Pharmaceuticals

Cipher Pharmaceuticals is a specialty pharmaceutical company with a diverse portfolio of commercial and developmental products, primarily in dermatology. The company focuses on acquiring products that address unmet medical needs and manages the clinical development and regulatory approval processes, marketing its products in Canada, the U.S., and South America.

Average Trading Volume: 24,920

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$361.9M

For a thorough assessment of CPH stock, go to TipRanks’ Stock Analysis page.